ReviewJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2023
Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.
Review in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Current indications for surgery in patients with lung cancer after neoadjuvant targeted therapy: a systematic review.Updates in surgery · 2026Pooled it
- Safety and efficacy of salvage surgery for unresectable hepatocellular carcinoma after conversion with triple therapy: a systematic review and meta-analysis of data from Chinese patients.World journal of surgical oncology · 2025Pooled it
- Efficacy of neoadjuvant PD-1/PD-L1 inhibitor in resectable NSCLC: a meta-analysis based on randomized controlled trials.BMC cancer · 2024Pooled it
- Neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA-IIIB non-small cell lung cancer: integrated multidimensional biomarker analysis from a phase II study.Journal for immunotherapy of cancer · 2026Trial
- A multicenter survey on BRAF screening for the implementation of perioperative cancer genomic medicine for resectable colorectal oligometastases.International journal of clinical oncology · 2026Article
- Radiographic tumor regression as a predictor for pathologic response after neoadjuvant therapy for non-small cell lung cancer.JTCVS open · 2026Article
- Deep learning-based computed tomography quantification integrated with circulating tumor cells for prognostic evaluation in stage I lung adenocarcinoma.Quantitative imaging in medicine and surgery · 2026Article
- PET/CT predict pathological response to neoadjuvant nivolumab in resectable non-small cell lung cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- USP37 facilitates hepatocellular carcinoma progression by deubiquitinating RAF1 and activating ERK1/2 signaling.Functional & integrative genomics · 2026Article
- Segmentectomy achieves comparable survival outcomes compared to lobectomy in peripheral ≤3 cm non-small cell lung cancer with occult lymph node metastases.Journal of thoracic disease · 2026Article
- Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).Chinese medical journal · 2026Review
- Neoadjuvant afatinib in a patient with locally advanced lung adenocarcinoma harboring an NPTN-NRG1 fusion: a case report.World journal of surgical oncology · 2026Article
- (-)-Epi-Osmundalactone-Rich Fraction fromPlants (Basel, Switzerland) · 2026Article
- Maximum standardized uptake value significance in clinical stage IB-IIIB non-small cell lung cancer.Journal of thoracic disease · 2026Article
- Construction of a postoperative disease-free survival prediction model for non-small cell lung cancer patients based on dual-energy computed tomography parameters and blood inflammatory indicators.Translational cancer research · 2026Article
- Review
- Real-world analysis of perioperative strategies for driver gene-positive resectable non-small cell lung cancer.Therapeutic advances in medical oncology · 2026Article
- Perioperative EGFR-Targeted Therapy in Resectable EGFR-Mutated NSCLC: A Narrative Review from Drug Design to Pain-Informed MRD-Guided Care.Drug design, development and therapy · 2026Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 9 institutions in 2 countries.
Funding
Abstract
The standard of care (SoC) for medically operable patients with early-stage (stages I-IIIB) NSCLC is surgery combined with (neo)adjuvant systemic therapy for patients with stages II to IIIB disease and some stage IB or, rarely, chemoradiation (stage III disease with mediastinal lymph node metastases). Despite these treatments, metastatic recurrence is common and associated with poor survival, highlighting the need for systemic therapies that are more effective than the current SoC. After the success of targeted therapy (TT) in patients with advanced NSCLC harboring oncogenic drivers, these agents are being investigated for the perioperative (neoadjuvant and adjuvant) treatment of patients with early-stage NSCLC. Adjuvant osimertinib is the only TT approved for use in the early-stage setting, and there are no approved neoadjuvant TTs. We discuss the importance of comprehensive biomarker testing at diagnosis to identify individuals who may benefit from neoadjuvant targeted treatments and review emerging data from neoadjuvant TT trials. We also address the potential challenges for establishing neoadjuvant TTs as SoC in the early-stage setting, including the identification and validation of early response markers to guide care and accelerate drug development, and discuss safety considerations in the perioperative setting. Initial data indicate that neoadjuvant TTs are effective and well tolerated in patients with EGFR- or ALK-positive early-stage NSCLC. Data from ongoing trials will determine whether neoadjuvant targeted agents will become a new SoC for individuals with oncogene-addicted resectable NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.